The Federal Response to COVID-19 February 8, 2023

Testimony | In Person

• Testimony of: Robert M. Califf, M.D., MACC ; Commissioner of Food and Drugs - Food and Drug Administration

INTRODUCTION

Chairs McMorris Rodgers, Griffith, and Guthrie, Ranking Members Pallone, Castor, and Eshoo, and distinguished members of the Committee, thank you for the opportunity to testify before you to discuss the Food and Drug Administration’s (FDA’s or the Agency’s) coronavirus disease 2019 (COVID-19) response and our preparedness efforts moving forward. Our efforts are in close coordination and collaboration with our partners, both within the Department of Health and Human Services (HHS) and across the federal government, to help facilitate the development, authorization, licensure, approval, and availability of critical, safe, and effective medical products to address current and future threats. 

The COVID-19 pandemic underscores the need to continue to optimize our preparedness and response capabilities. The Agency’s continued preparedness for, and capabilities to respond to, public health emergencies and disease threats such as COVID-19, mpox, respiratory syncytial virus and pandemic influenza have been strengthened by Congress’ support of our work. We look forward to continuing work with you this Congress to ensure future readiness.

Click for full version of testimony